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Abstract:  
In the retina, peptidergic signalling participates in multiple circuits of visual information processing. 
The neuropeptide somatostatin (SRIF) is localised to amacrine cells and, in some instances, in a 
subset of ganglion cells. The variegated expression patterns of SRIF receptors (sst1-sst5) and the 
variety of signalling mechanisms activated by retinal SRIF suggest that this peptide may exert 
multiple actions on retinal neurons and on retinal physiology, although our current understanding 
reflects a rather complicated picture. SRIF, mostly through sst2, may act as a positive factor in the 
retina by regulating retinal homeostasis and protecting neurons against damage. In this respect, 
SRIF analogues seem to constitute a promising therapeutic arsenal to cure different retinal diseases, 
as for instance ischemic and diabetic retinopathies. However, further investigations are needed not 
only to fully understand the functional role of the SRIF system in the retina but also to exploit new 
chemical space for drug-like molecules. 
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1. Retina and neuropeptides 
The defined input of the mammalian retina, its discrete output, accessibility, laminar organisation, 
and small number of principal cell types have promoted an understanding of retinal circuitry and 
structure-functional relationship. Beside its use for investigations on visual information processing, 
the mammalian retina has been extensively used as an experimental model of the central nervous 
system. Indeed, it is part of the central nervous system and it is separated at the same time, allowing 
easy experimental approaches. In addition, the mammalian retina displays the complexity typical of 
the brain while having an ordered, layered structure that is conserved throughout its extension (Fig 
1). The retina is composed of five principal neuronal cell types, including photoreceptors (the light 
sensitive cells in the retina), bipolar, horizontal, amacrine, and ganglion cells. A sixth type is that of 
interplexiform cells, that may be considered an amacrine cell variant. The basic circuitry within the 
retina directs the flow of visual information from photoreceptors, through bipolar cells, to ganglion 
cells, which are the only output neurons and with their axons constitute the retinofugal projections 
to the brain. Two horizontal pathways modulate this flow: one provided by horizontal cells in the 
outer retina, the other formed by amacrine cells in the inner retina. Horizontal cells are strongly 
electrically coupled and integrate light signals over a large retinal area. They feedback onto 
photoreceptors, and contact bipolar cells. Thus, inputs from a large surround region of the retina 
influence photoreceptors and bipolar responses, providing the bipolar cell with a centre-surround 
organisation.  
The most heterogeneous retinal cell type is that of amacrine cells, which can be divided into 
numerous populations on the basis of their neurochemical phenotypes. In this regard, a wide variety 
of neuroactive substances are expressed in the mammalian retina. Over the last three decades, 
several neuropeptides have been investigated and some knowledge is now available of their 
potential physiological relevance (Bagnoli et al., 2003). In particular, neuropeptides are principally 
expressed by populations of sparsely distributed, mostly GABAergic amacrine cells and by some 
ganglion cells. In contrast, neuropeptide receptors are expressed by variegated retinal cell 
populations, suggesting that peptidergic signalling participates in multiple circuits of visual 
information processing. Among neuropeptides, somatostatin, or somatotropin release inhibiting 
factor (SRIF), has been widely investigated in the retina. SRIF is produced from a single gene in 
two bioactive products: SRIF-14 and SRIF-28 (Olias et al., 2004). SRIF produces its effects by 
activating five heptahelical transmembrane G-protein coupled receptors, which have been cloned 
and named sst1 to sst5 in accordance with IUPHAR recommendations (Hoyer et al., 1995). Here, we 
provide a review of the latest advances on the role of SRIF and its receptors in the mammalian 
retina. 
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2. The somatostatinergic system in the retina 
The expression and the localisation of SRIF and of its receptors (both at mRNA and at protein 
level) in mammalian retinas has been reviewed in recent years (Casini et al., 2005; Thermos, 2003). 
There is a general agreement that such a distribution reflects the pleiotropic functions of retinal 
SRIF as a result of the multiple signalling actions of its receptors. 
 
2.1. Expression of somatostatin 
In general, SRIF immunoreactivity is localised to sparsely distributed, wide-field amacrine and/or 
displaced amacrine cells and, in some instances, in a subset of ganglion cells. In particular, in the 
mouse (Cristiani et al., 2002), rat (Larsen et al., 1990; Sagar et al., 1985), guinea pig (Spira et al., 
1984; Tornqvist et al., 1982) and human retina (Tornqvist and Ehinger, 1988), SRIF-containing 
cells are detected in both the inner nuclear layer and the ganglion cell layer. In the mouse retina, the 
population of SRIF-containing amacrine cells is sparsely distributed to all retinal regions, while the 
population of displaced amacrine cells is confined to the ventral retina (Cristiani et al., 2002). In the 
rabbit, cat and primate retina, most SRIF immunoreactive cells are displaced amacrine cells that are 
predominantly distributed to the ventral retina (Engelmann and Peichl, 1996; Rickman et al., 1996; 
White et al., 1990; Marshak, 1989; Mitrofanis et al., 1989; Sagar and Marshall, 1988; Sagar, 1987). 
In spite of the very sparse distribution of SRIF somata, SRIF processes extensively arborise in the 
inner plexiform layer of all retinal regions. A few ganglion cells displaying SRIF immunoreactivity 
have been reported in the retina of the new world monkey Tupaia belangeri (Engelmann and Peichl, 
1996) and of the cat, where these SRIF-immunoreactive ganglion cells have been identified as a 
small subset of OFF-center alpha ganglion cells, mostly localised to the inferior retina (White and 
Chalupa, 1991). Finally, a transient population of SRIF-containing ganglion cells has been 
discovered in the rat retina during postnatal development (Xiang et al., 2001; Fontanesi et al., 
1997). 
 
2.2. Expression of somatostatin receptors 
Immunohistochemical data show that SRIF receptors are expressed by a variety of retinal cell 
populations. In rat, rabbit and mouse retinas, sst1 is predominantly expressed by SRIF-containing 
amacrine cells (Dal Monte et al., 2003b; Cristiani et al., 2000; Helboe and Moller, 1999). In the 
rabbit retina, it is also found on all the dopaminergic amacrine cells (Cristiani et al., 2000). Of the 
two sst2 isoforms, sst2A has been localised in rat, rabbit and mouse retinas, where it displays slightly 
different patterns (Cristiani et al., 2002; Petrucci et al., 2001; Vasilaki et al., 2001; Fontanesi et al., 
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2000; Helboe and Moller, 1999; Johnson et al., 1999; Johnson et al., 1998). In the rat retina, sst2A 
has been localised to amacrine cells, including tyrosine hydroxylase-containing amacrine cells, to 
rod and cone bipolar cells and to horizontal cells (Johnson et al., 1999). In rabbits, these receptors 
are expressed mainly by rod bipolar and by sparsely distributed amacrine cells that have been 
reported to lack (Johnson et al., 1998) or to partially express (Fontanesi et al., 2000) tyrosine 
hydroxylase immunoreactivity. In the mouse retina, sst2A immunoreactivity has been reported in rod 
bipolar cells, horizontal cells, and in amacrine cells (Fig 2), including glycinergic amacrine cells 
and the population of tyrosine hydroxylase-containing, dopaminergic amacrine cells (Cristiani et al., 
2002). The sst2B isoform in the rat retina is predominantly found on the membrane of 
photoreceptors, indicating SRIF actions in the outer retina (Vasilaki et al., 2001). In the human 
retina, both sst1 and sst2A have been immunohistochemically localised throughout all retinal layers 
(Klisovic et al., 2001; van Hagen et al., 2000) and in endothelial cells of retinal blood vessels 
(Klisovic et al., 2001). Regarding sst4, it has been identified with immunohistochemistry in sparse 
ganglion cells of the mouse retina (Cristiani et al., 2002). Finally, sst5 has been recently reported in 
cholinergic, dopaminergic and SRIF-containing amacrine cells and in putative ganglion cells of the 
rat retina (Ke and Zhong, 2007). These data appear to be in contrast with a previous work reporting 
lack of sst5 immnuoreactivity in the rat retina (Vasilaki et al., 2002). Data concerning the retinal 
localization of sst3 are not available, however its mRNA has been detected in rat (Mori et al., 1997), 
mouse (Cristiani et al., 2002), and human (Klisovic et al., 2001; van Hagen et al., 2000) retinas. 
Profound alterations of the levels of SRIF expression as well as of that of specific ssts have been 
detected in retinas of mice in which sst1 or sst2 genes are genetically deleted (Casini et al., 2004; 
Dal Monte et al., 2003b). In particular, although changes in the expression of SRIF mRNA have not 
been reported in these knock-out (KO) retinas, sst1 deletion causes an increased content of SRIF 
peptide, whereas SRIF content decreases after sst2 loss. In addition, sst1 and sst2 have been found to 
compensate for each other. Indeed, as a consequence of sst1 deletion, sst2 becomes overexpressed, 
whereas in sst2 KO retinas, sst1 expression is drastically increased. The fact that SRIF binding sites 
in sst1 KO retinas have a density similar to that of wild-type (WT) retinas suggests that the relative 
proportion of SRIF receptors does not change as a consequence of sst1 deletion and indicates that 
the loss of sst1 can be totally compensated by an increase in sst2. Compensatory mechanisms at the 
level of SRIF receptor density also occur in the absence of SRIF since an upregulation of SRIF 
binding sites has been recently reported in SRIF KO mouse retinas (Mastrodimou et al., 2006b). In 
addition, in these retinas, all SRIF receptor mRNAs, with the only exception of sst4 mRNA, are 
expressed at significantly higher levels than in WT retinas (Casini et al., 2005). 
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2.3. Signalling mechanisms  
It is generally accepted that the pleiotropic cellular functions of SRIF are a result on the one hand of 
the widespread distribution of the SRIF system, and on the other of the variety of signalling 
mechanisms activated by SRIF receptors (Cervia and Bagnoli, 2007). In particular, as summarised 
in Table 1, SRIF receptor activation leads to the modulation of different signalling elements, 
including adenylyl cyclase, guanylyl cyclase, phospholipase C, phospholipase A2, nitric oxide, K
+
 
and Ca
2+
 channels, Na
+
/H
+
 exchanger, phosphatases, mitogen-activated kinases and 
phosphatidylinositol 3 kinases (Cervia and Bagnoli, 2007; Cervia et al., 2005b). These data have 
been collected mainly over the last decade using in vitro systems of recombinant and/or native 
models. In addition, different SRIF analogues may induce distinct conformations of the 
receptor/ligand complex, preferentially coupled to receptor signalling (Tulipano and Schulz, 2007). 
For these reasons, our current understanding of receptor subtype-selective signalling reflects a 
rather complicated picture and parallels between these data and the real in vivo conditions are not so 
obvious.  
 
2.3.1. Signalling mechanisms in the retina 
At present, little is known about SRIF signalling in the mammalian retina. For instance, SRIF 
inhibits adenylyl cyclase activity in the sheep retina (Colas et al., 1992). In contrast, it increases 
adenylyl cyclase activation in amacrine cells of the rat retina (Feigenspan and Bormann, 1994). 
Where the specific receptor subtype involved has been studied, it has been found that sst2 inhibits 
adenylyl cyclase activity in the mouse retina, probably through Go -proteins (Pavan et al., 2004). 
sst2 coupling to Go -proteins has been also demonstrated in the rabbit retina (Vasilaki et al., 2003). 
Interestingly, in the mouse retina, sst1 inhibits adenylyl cyclase activity only after elimination of the 
sst2 response, suggesting that there may be interactions between sst1 and sst2 when they signal via 
adenylyl cyclase (Pavan et al., 2004). In addition, although NADPH diaphorase staining does not 
colocalise with sst1, sst2 or sst4 in the mouse retina (Mastrodimou et al., 2006b), the colocalisation 
of sst2 with NADPH diaphorase in rod bipolar cells and photoreceptor cells of both rat and rabbit 
retinas has been reported (Vasilaki et al., 2001), suggesting a role of SRIF in the regulation of nitric 
oxide. Consistently, sst2 activates nitric oxide synthase in human retinal pigment epithelial cells 
(Vasilaki et al., 2004) and in the rat retina (Vasilaki et al., 2002). Once generated, nitric oxide does 
not exert its effect via specific receptors but it diffuses across synaptic membranes to activate 
soluble guanylate cyclase, thus increasing intracellular levels of cGMP. Accordingly, in the rat 
retina, sst2 has been recently shown to mediate SRIF-induced increase of cGMP levels 
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(Mastrodimou et al., 2006a). Regarding the control of K
+
 and Ca
2+
 conductances, SRIF, acting at 
sst2, induces a prominent inhibition of large-conductance, Ca
2+
- and voltage-dependent K
+
 channels 
as well as an inhibition of K
+
-induced increase of the intracellular Ca
2+
 concentration ([Ca
2+
]i) in 
rod bipolar cells isolated from the rabbit retina (Petrucci et al., 2001). sst2 negative coupling to K
+
 
conductances has been also demonstrated in rod bipolar cells isolated from the mouse retina 
(Bigiani et al., 2004). In the same experimental model, sst2 inhibits the K
+
-induced increase of 
[Ca
2+
]i both in the cell body and in the axonal terminals (Casini et al., 2005). Similarly, in the 
axonal terminals of rod bipolar cells isolated from the rat retina, SRIF strongly inhibits a K
+
-
induced increase of [Ca
2+
]i via L-type Ca
2+
 channels (Johnson et al., 2001). This effect of SRIF is 
likely to be mediated by sst2 receptors.  
 
2.4. Functional role 
The first observations of SRIF effects on mammalian retinal physiology reported an influence of the 
peptide on the amplitude of the ERG b-wave in the rabbit retina in vivo (Cunningham and Neal, 
1983), while some years later Zalutsky and Miller (1990), working with rabbit eyecup preparations, 
found that application of low concentrations of SRIF affects the amplitude of the a-, b- and c-waves. 
In their seminal work, Zalutsky and Miller also investigated the effects of SRIF application on the 
activity of different retinal cell types, demonstrating that SRIF actions are characterised by slow 
onset and long latency and providing the first account of the complexity of SRIF functional actions 
in the retina. Briefly, SRIF was observed to directly affect bipolar, amacrine and ganglion cells and 
to influence the horizontal cell network. In particular, all ganglion cell types are excited by SRIF, 
which also affects the centre-surround balance of their receptive fields.  
The localisation of some of the SRIF receptors at locations that are distant from the sites of SRIF 
release in the inner plexiform layer suggests that this peptide may act in a paracrine fashion. In 
particular, SRIF functions are likely to result from the actions exerted by SRIF onto other 
neurotransmitter systems in the retina, including the release of SRIF itself. These effects are 
consistent with the documented SRIF control of K
+
/Ca
2+
 conductances as well as the nitric 
oxide/cGMP pathway, which has been recently coupled to neurotransmission in the inner retina 
(Ding and Weinberg, 2007). In addition, at the level of outer retina, SRIF coupling to Ca
2+
- 
dependent mechanisms provides important regulation of both rod and cone photoreceptor function, 
including transduction and synaptic transfer of light stimuli. In particular, in the outer segment, Ca
2+
 
controls photoreceptor light adaptation, while in the inner segment and synaptic terminal, Ca
2+
 is 
involved in the regulation of cellular metabolism, glutamate release, cytoskeletal dynamics, gene 
expression and cell death (Krizaj and Copenhagen, 2002).  
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2.4.1. Somatostatin control of its own release 
SRIF may regulate its own release through sst1 in different systems, including the retina (Thermos 
et al., 2006). In particular, the observation that sst1 is expressed by all SRIF-containing amacrine 
cells strongly suggests that sst1 acts as an autoreceptor to limit SRIF release. Indeed, functional 
studies in rat retinal explants firmly established that sst1 activation decreases SRIF release (Thermos 
et al., 2006; Mastrodimou and Thermos, 2004). Additional, although indirect, evidence of the 
autoreceptor function of sst1 derives from studies in sst1 or sst2 KO mouse retinas. As mentioned 
above, sst1 KO retinas are characterised by increased levels of SRIF peptide, while sst2 KO retinas 
display a significant decrease of retinal SRIF. These observations suggest that the amount of retinal 
SRIF is likely to depend on the expression levels of sst1 (Casini et al., 2004): in the absence of sst1 
(as in sst1 KO retinas) inhibitory mechanisms limiting SRIF levels in the retina would be removed, 
while in the presence of sst1 over-expression (as in sst2 KO retinas) such mechanisms would be 
strengthened.  
 
2.4.2. Somatostatin control of dopamine release 
Based on the expression of SRIF receptors by tyrosine hydroxylase-containing, dopaminergic 
amacrine cells, SRIF control of dopamine release has been postulated in mouse, rat and rabbit 
retinas, although there are differences in the individual SRIF receptors that may mediate this 
control. The direct demonstration of an influence of SRIF on retinal dopamine release has been 
recently provided by Thermos and colleagues (Kouvidi et al., 2006), who showed that activation of 
either sst1 or sst2 causes an increase of dopamine release in rat retinal explants, while activation of 
sst3 has no effect. Since retinal levels of dopamine are known to be positively correlated with light 
intensity (Boelen et al., 1998; Djamgoz and Wagner, 1992), this SRIF control of dopamine release 
is likely to have importance for the regulation of light adaptation. 
 
2.4.3. Somatostatin control of glutamate release 
Glutamate is the major excitatory neurotransmitter in the mammalian retina, and it is implicated in 
the neurotransmission along the vertical visual pathway from photoreceptors to bipolar cells to 
ganglion cells. A common trait of the somatostatinergic system among different mammalian retinas 
is the expression of sst2A in rod bipolar cells, which represent a major source of glutamate in the 
retina. This observation indicates that an important, conserved functional role of SRIF in the retina 
is the regulation of glutamate release through an action at sst2. Consistently, sst2 activation has been 
shown to inhibit K
+
-induced glutamate release in mouse retinal explants (Dal Monte et al., 2003a). 
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In addition, the SRIF-induced inhibition of glutamate release is significantly stronger when sst2 is 
over-expressed, as in sst1 KO retinas (Bigiani et al., 2004). A further indication that SRIF may limit 
glutamate release acting at sst2 comes from recent studies where glutamate release was induced by 
ischemic treatment in a mouse retina preparation in vitro: in these conditions, glutamate release was 
significantly reduced in sst1 KO retinas in comparison to WT retinas (Catalani et al., 2007). 
Together, these data concur to the notion that the SRIF system in the retina is an important regulator 
of the concentration of released glutamate in the extracellular space. This function is likely to 
represent an important contribution to the regulation of the glutamatergic transmission along the 
vertical retinal visual pathway. In addition, by limiting the amount of glutamate available to 
glutamate receptors, SRIF may also exert an important neuroprotective function against glutamate 
neurotoxicity that characterises many retinal diseases (see point 3). 
 
2.4.4. Somatostatin effects on other neurotransmitters 
The localisation of SRIF receptors to different types of amacrine cells in the inner nuclear layer, 
including glycine containing amacrine cells (Cristiani et al., 2002), some cells likely belonging to 
subpopulations of GABAergic amacrine cells (Ke and Zhong, 2007; Cristiani et al., 2002), or to 
horizontal cells, which are considered to be GABAergic (Vardi and Sterling, 1994), suggests that 
SRIF may participate to the regulation of the retinal levels of these important inhibitory 
transmitters. Although functional evidence for a SRIF control of glycine release is lacking, SRIF 
has been suggested to enhance GABAergic transmission through phosphorylation of GABAA 
receptors in amacrine cells of the rat retina (Feigenspan and Bormann, 1994). This possibility is 
intriguing in view of the fine control that GABAergic amacrine cells exert on transmitter release 
from rod bipolar cell terminals through GABAC receptors (Vaquero and de la Villa, 1999). If these 
GABAergic amacrine cells respond to a regulation by SRIF, this peptide would be able to control 
glutamate release by the rod bipolar cells through two distinct mechanisms: a direct action onto the 
sst2A expressing rod bipolar cells, and an indirect action by regulating GABA release from amacrine 
cells. 
The fact that sst5 may be expressed by cholinergic amacrine and displaced amacrine cells (Ke and 
Zhong, 2007), suggests that SRIF may be involved in the control of acetylcholine release. However, 
earlier investigations showed that SRIF does not change the level of light-evoked release of 
acetylcholine from rabbit retina (Cunningham and Neal, 1983). 
 
3. The somatostatinergic system in retinal diseases 
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The wide anatomical distribution and multiple actions of SRIF and its receptors have stimulated 
intense clinical studies, and the SRIF system is currently a therapeutic target for different 
pathological conditions (Cervia and Bagnoli, 2007; Panteris and Karamanolis, 2005; Weckbecker et 
al., 2003). SRIF analogues are either peptidic or non-peptidic compounds that equally bind to the 
majority of SRIF receptors (Armani et al., 2007; Ludvigsen et al., 2007; Nolan et al., 2007; Zatelli 
et al., 2007; Batista et al., 2006; Cervia et al., 2005a; van der Hoek et al., 2005; van der Hoek et al., 
2004; Lewis et al., 2003; Reubi et al., 2002), or are selective for a specific SRIF receptor subtype or 
class (Cervia et al., 2005b; Olias et al., 2004; Weckbecker et al., 2003). In addition, the emergence 
of novel multispecific SRIF analogues (compounds targeting different cellular receptors) and 
conjugates (synthesised by chemically linking SRIF analogues with other agents) with improved 
receptor specificity may produce a new generation of potential drugs (Dasgupta, 2004). On the basis 
of laboratory findings, the possible clinical use of SRIF analogues in ophthalmology has been 
suggested (Casini et al., 2005; Missotten et al., 2005). However, difficulties with the route of 
administration, dosage, and adverse effects may compromise the translation to the clinics. 
 
3.1. Retinal ischemia 
Ischemia deprives a tissue of three requirements: oxygen, metabolic substrates, and removal of 
waste products. The loss of these requirements will initially lower homeostatic responses and with 
time will induce injury to the tissue due to cell loss by apoptosis (Osborne et al., 2004). Ischemia 
can be considered as a sort of final common pathway in retinal diseases. It is a primary cause of 
neuronal death and is a common cause of visual impairment and blindness. To contrast this 
pathological state, specific pharmacological strategies need to be developed aimed at the many 
putative cascades generated during ischemia (Osborne et al., 2004). Among pharmacological 
targets, the SRIF system is a candidate that is being subjected to intensive investigation. Indeed, 
there is evidence that retinal SRIF may act as a neuroprotective agent in ischemic retinas (Casini et 
al., 2005). In particular, in guinea pig retinas, octreotide (a long-lasting sst2 preferred agonist) 
protects against ischemia-reperfusion injury (Celiker and Ilhan, 2002) and sst2 agonists attenuate 
cell death in rat retinal explants subjected to chemical ischemia (Mastrodimou et al., 2005). 
Recently, an altered expression of SRIF receptors has been shown to modulate retinal responses to 
cell damage in an in vitro model of the ischemic mouse retina (Catalani et al., 2007). In particular, 
sst1 KO retinas, where sst2 are over-expressed and over-functional, display a marked reduction of 
cell death with respect to WT or sst2 KO retinas. In addition, the expression of protease caspase-3 
mRNA, a marker of apoptotic cell death, is also reduced in sst1 KO as compared to WT retinas. 
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Taken together, these observations demonstrate that an increased presence/activation of functional 
sst2 protects against retinal ischemia.  
Immunohistochemical analyses have identified some of the retinal cell populations that are 
protected by sst2 activation. In particular, in explants of the rat retina subjected in vitro to chemical 
ischemia, sst2 agonists prevent, at least in part, the loss of several retinal cell populations, including 
choline acetyltransferase-, tyrosine hydroxylase-, nitric oxide synthase-positive amacrine cells as 
well as the rod bipolar cells (Mastrodimou et al., 2005). On the other hand, other studies in a model 
of in vitro ischemia of the mouse retina have recently demonstrated that the extent of sst2-mediated 
protection may vary among different retinal cell populations (Catalani et al., 2007), suggesting a 
high level of complexity within the neuroprotective mechanisms of sst2. For instance, it is 
interesting to note that the population of rod bipolar cells, which express sst2 at high levels, is 
severely affected by ischemia, but it is significantly spared in the presence of sst2 overexpression, as 
in sst1 KO retinas, while it is more heavily damaged in the absence of sst2, as in sst2 KO retinas 
(Fig. 3).  
It is generally accepted that an important component of ischemic retinal injury involves neuronal 
depolarisation and increased glutamatergic stimulation. Other factors may also play a part in 
neuronal susceptibility during ischemia and they include the ability to modulate Ca
2+
 homeostasis, 
extracellular pH and the cells’ ability to quench free radicals (Osborne et al., 2004). Regarding the 
mechanism of action underlying SRIF neuroprotective effects in mouse ischemic retinas, sst2 may 
act through the involvement of presinaptically sst2-mediated modulation of K
+
 and Ca
2+
 
conductances leading to cell hyperpolarisation, [Ca
2+
]i decrease and reduction of glutamate release 
(see paragraph 2.4.3.). sst2 may also regulate, postsinaptically, NMDA receptor activation by 
glutamate as well as K
+
 and Ca
2+
 voltage-dependent channels. Neuroprotective effects of SRIF on 
NMDA-induced neuronal death have been previously shown in rats (Forloni et al., 1997). In 
addition, in an in vitro model of chemical ischemia of the mouse retina, it has been recently 
demonstrated that not only retinal glutamate release increases under ischemic conditions (consistent 
with a role of glutamate excitotoxicity in ischemia-induced neuronal death), but also that this 
increase is significantly reduced in sst1 KO retinas, indicating that the protection provided by 
increased presence of functional sst2 is likely to be mediated by sst2 modulation of glutamate release 
(Catalani et al., 2007). Other mechanisms may also participate in the protective role of SRIF against 
retinal ischemia, such as an sst2-mediated regulation of nitric oxide, an important mediator in the 
pathogenesis of retinal ischemic damage (Osborne et al., 2004). However, in guinea pig retinas, 
SRIF analogues do not seem to influence nitric oxide activity, which is decreased as a consequence 
of retinal ischemia-reperfusion (Celiker and Ilhan, 2002). 
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3.2. Diabetic retinopathy 
The concept that ischemia is the driving force for new vessel formation in the retina can be traced 
back over 50 years (Osborne et al., 2004). Indeed, retinal ischemia is commonly caused by vascular 
closure with liberation of vasoproliferative factors, which in turn produces neovascularisation. 
Ocular neovascularisation and the associated hemorrhages and fibrovascular proliferations are the 
underlying threats to vision in diverse conditions such as diabetic retinopathy, a leading cause of 
visual loss in industrialised countries. Laser photocoagulation remains the only procedure 
recommended for severe nonproliferative or proliferative retinopathy (Porta and Allione, 2004), but 
this is an invasive procedure and provides only temporary protection (Croxen et al., 2004). Less 
destructive approaches are desirable, and the use of SRIF analogues is currently tested in clinical 
trials with some success (Boehm, 2007; Palii et al., 2007; Croxen et al., 2004; Sjolie and Moller, 
2004).  
SRIF levels in the vitreous of patients with diabetic retinopathy are significantly lower than those in 
nondiabetic control subjects (Hernandez et al., 2005; Simo et al., 2002). This observation suggests 
that the intravitreous deficit of SRIF may contribute to the process of retinal neovascularisation 
typical of proliferative retinopathy and supports the concept that adequate levels of SRIF are needed 
for the maintenance of retinal homeostasis. Furthermore, there is a general agreement that SRIF 
may contrast neovascularisation associated with diabetic retinopathy, although the mechanism of 
action remains to be elucidated (Boehm, 2007; Casini et al., 2005). Angiogenesis is a complex 
process, but it may be regarded as the result of changes in the equilibrium between anti- and pro-
angiogenic factors. For instance, the insulin-like growth factor-1 (IGF-1), stimulated by growth 
hormone, increases in the vitreous of diabetic retinopathy patients (Simo et al., 2002), and it is a 
major pro-angiogenic factor (DeBosch et al., 2001). SRIF analogues are powerful inhibitors of 
growth hormone release and, therefore, decrease the blood IGF-1 concentration. Thus, SRIF may 
exert its antiangiogenic effects on the retina through antagonism of the growth hormone axis 
(Boehm, 2007; Wilkinson-Berka et al., 2006; Garcia de la Torre et al., 2002). On the other hand, 
SRIF may inhibit retinal angiogenesis through autocrine and paracrine effects, perhaps directly on 
retinal cells or on retinal blood vessels (Boehm, 2007; Baldysiak-Figiel et al., 2004; Dasgupta, 
2004; Garcia de la Torre et al., 2002; Higgins et al., 2002). These effects are likely to include 
regulation of the levels of angiogenesis-associated factors that are expressed in the retina, such as 
IGF-1/IGF-1 receptors and vascular endothelial growth factor (VEGF)/VEGF receptors. In 
particular, IGF-1 not only is in the blood depending on the levels of circulating growth hormone 
(see above), but it and its receptors are also expressed throughout the retina in vascular, neuronal 
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and glial cells, and they are altered by hyperglycaemia and hypoxia (Wilkinson-Berka et al., 2006). 
For instance, the levels of IGF-1 receptor mRNA are increased in the retinas of mouse models of 
both diabetic retinopathy (Kuang et al., 2003) and hypoxia-induced proliferative retinopathy (Dal 
Monte et al., 2007), although conflicting results have been reported in rat retinas (Leske et al., 2006; 
Leske et al., 2004; Averbukh et al., 1998). Regarding the VEGF system, diabetic retinopathy and 
hypoxia/acidosis-induced proliferative retinopathy have been shown to cause overexpression of 
retinal levels of VEGF and its receptors, thus increasing microvascular permeability and 
angiogenesis (Dal Monte et al., 2007; Leske et al., 2004; Werdich et al., 2004; Witmer et al., 2003; 
McLeod et al., 2002; Witmer et al., 2002; Ellis et al., 2000; Gilbert et al., 1998). In a recent analysis 
of hypoxia-induced neoangiogenic retinas of sst1/sst2 KO mice, we have demonstrated that lack of 
sst2, as in sst2 KO retinas, is associated with significantly higher levels of neovascularisation. 
Moreover, enhanced SRIF function at sst2, as in sst1 KO retinas, limits the hypoxia-induced increase 
of the pro-angiogenic VEGF, whereas sst2 loss upregulates this increase (Fig. 4). In addition, the 
expression of the angiopoietin-1/2 and their receptors, which have different roles in the 
angiogenetic process, is dysregulated in the absence of sst2. (Dal Monte et al., 2007). These 
observations provide evidence that sst2 may be  beneficial in limiting hypoxia-induced 
neovascularisation in the retina (Dal Monte et al., 2007; Kociok et al., 2006; Takagi et al., 2003). 
Another mechanism which may underlie anti-angiogenic effects of SRIF includes the involvement 
of the protein kinase CK2 (formerly casein kinase 2), an ubiquitous serine/threonine protein kinase 
that is involved in a wide variety of biological processes, including retinal angiogenesis and 
pathogenesis of diabetic and other proliferative retinal microangiopathies (Ljubimov et al., 2004). 
Indeed, a cross-talk between sst2 and the CK2 pathway has been suggested on the basis that 
octreotide, combined with CK2 inhibitors, blocks retinal neovascularisation in a mouse model of 
oxygen-induced retinopathy more efficiently than either compound alone (Kramerov et al., 2006). 
 
4. Conclusion 
Although far from being fully elucidated, SRIF modulation of ionic conductances, intracellular 
effectors and transmitter release in the retina may account for the observed effects of SRIF on 
retinal visual processing. In addition, SRIF may act as a positive factor in the retina by regulating 
retinal homeostasis and protecting neurons against damage. In this respect, SRIF analogues seem to 
constitute a promising therapeutic arsenal to cure different retinal diseases and their clinical 
applications are the object of numerous studies. However, further investigations are needed not only 
to fully understand the functional role of the SRIF system in the retina but also to exploit new 
chemical space for drug-like molecules. 
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Legends to Figures 
 
Fig. 1. Schematic representation of the mammalian retina. All the principal neuronal types are 
depicted. Retinal layers are named on the right. The incoming light (arrow on the lower left) 
passes through the whole retinal thickness before reaching the photoreceptors (rods and 
cones). The vertical pathway of visual information processing, together with lateral 
influences at the level of horizontal cells are also shown. 
 
Fig. 2. sst2A immunofluorescence in a whole mouse retina showing sst2A expression by amacrine 
cells and their processes. The large, intensely labelled cells are tyrosine hydroxylase-
containing, dopaminergic, wide-field amacrine cells. The dense network of immunolabelled 
processes, localised to the inner plexiform layer, is formed by processes originating from the 
dopaminergic amacrine cells and from other, smaller amacrine cells containing glycine. 
Scale bar, 50 μm. 
 
Fig. 3. Rod bipolar cells immunolabelled with antibodies directed to protein kinase C in control 
retinas and in wild-type (WT), sst1 KO or sst2 KO retinas subjected to ischemic treatment. 
Rod bipolar cells are less affected by ischemia in sst1 KO retinas, while they are more 
severely damaged in sst2 KO retinas. The sections were counterstained with 4’-6-diamidino-
2-phenylindole. Scale bar, 20 μm. 
 
Fig. 4. VEGF immunostaining in control retinas and in wild-type (WT), sst1 KO or sst2 KO retinas 
subjected to hypoxic treatment. VEGF expression significantly increases both in retinal cells 
and in retinal blood vessels of WT retinas treated for hypoxia. This increase is attenuated in 
the presence of sst2 overexpression (as in sst1 KO retinas), while it is enhanced in the 
absence of sst2 expression (as in sst2 KO retinas). Scale bar, 20 μm. 
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